Ipilimumab extends relapse-free survival in resectable melanoma

vandetanib improves PFS in thyroid cancer

E-hospital: Fully coordinated cancer care and research in Europe

ESMO Highlights: Breast cancer

Combination of capecitabine and bevacizumab improves progression-free survival in metastatic breast cancer

Cancer care in developing countries

Dabrafenib plus trametinib preferable to vemurafenib alone in melanoma

Nivolumab potentially superior to standard chemo in advanced melanoma

Targeted therapy for iodine-refractory thyroid cancer

Questions raised about the future of lung cancer vaccination?

Improved response rate and survival with dabrafenib plus trametinib versus vemurafenib alone in melanoma

Vemurafenib plus cobimetinib achieves significant progression-free survival in melanoma